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Abstract
Background: Night work is associated with disturbed sleep and wakefulness, particularly in
relation to the night shift. Circadian rhythm sleep disorders are characterized by complaints of
insomnia and excessive daytime sleepiness that are primarily due to alterations in the internal
circadian timing system or a misalignment between the timing of sleep and the 24-h social and
physical environment.
Methods: We evaluated the effect of oral intake of 5 mg melatonin taken 30 minutes before night
time sleep on insomnia parameters as well as subjective sleep onset latency, number of awakenings,
and duration of sleep. A double-blind, randomized, placebo-controlled crossover study with
periods of 1 night and washouts of 4 days comparing melatonin with placebo tablets was conducted.
We tried to improve night-time sleep during recovery from night work. Participants were 86 shift-
worker nurses aged 24 to 46 years. Each participant completed a questionnaire immediately after
awakening.
Results: Sleep onset latency was significantly reduced while subjects were taking melatonin as
compared with both placebo and baseline. There was no evidence that melatonin altered total sleep
time (as compared with baseline total sleep time). No adverse effects of melatonin were noted
during the treatment period.
Conclusion: Melatonin may be an effective treatment for shift workers with difficulty falling asleep.
Background
There is substantial evidence that the prevalence of sleep
disorders is an important occupational health problem,
especially among health care professionals on night or on
rotating work shifts [1-10]. An important aspect of the
work environment of nurses is that they are required to
work at any point in the 24 hour day [11]. Night work is
associated with disturbed sleep and impaired alertness.
The impact of sleep is the result of the circadian interfer-
ence with sleep during daylight hours and circadian sup-
pression of pineal gland by light at night [12].
The definition of insomnia is a complaint of disturbed
sleep, manifested as difficulties in sleep initiation, sleep
maintenance, early morning awakenings, or nonrestora-
tive sleep. Many sources also add the presence of associ-
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ated daytime impairments, such as fatigue, irritability,
decreased memory and concentration, and pervasive
malaise affecting many aspects of daytime functioning
[13]. In a recent study, 32% of night-shift workers
reported symptoms of insomnia or excessive daytime
sleepiness, whereas these symptoms were reported in only
18% of day workers from the same sample population
[14]. Several studies have reported that sleep problems are
more common among health care personnel on rotating
work shifts [15]. The quality of sleep has been found to be
altered in hospital nurses working on rotating shift sched-
ules, especially those working morning and night shifts as
well as in hospital nurses working shifts when compared
with day nurses [16].
The pineal hormone melatonin regulates a variety of
physiological processes, including circadian, cardiovascu-
lar, reproductive, and neuroendocrine functions [17-19].
However, it is the hypnotic effects of melatonin that are
considered an integral component of its physiological role
in sleep modulation [20,21]. Administration of mela-
tonin facilitates sleep onset and improves the quality of
sleep [22-24]. Administration of melatonin can also pro-
duce phase shifts in circadian rhythms, and has been used
to treat the symptoms of circadian maladaptation associ-
ated with shift work [25-27]. There is currently a great deal
of interest in whether properly timed melatonin adminis-
tration can facilitate circadian phase shifting in these situ-
ations [28].
Normally, production of melatonin by the pineal gland is
stimulated by darkness and inhibited by light [29]. Hajak
et al [30] reported lower levels in blood melatonin in
patients with insomnia than in healthy controls, and
Haimov et al [31] found lower levels of urinary 6-sulpha-
toxymelatonin in elderly patients with insomnia than in
healthy elderly subjects. Surprisingly, only a few studies
have explored the beneficial effect of melatonin adminis-
tration on night shift workers in an actual workplace set-
ting [26]. The purpose of this study was to compare the
efficacy of melatonin (5 mg) and placebo in the treatment
of shift workers with insomnia.
Methods
Study Design
We conducted a double-blind, placebo-controlled, rand-
omized crossover trial among healthy, non-smoking,
non-pregnant shift worker nurses at Imam Hospital
(Tehran, Iran). Each subject signed an informed consent
document after the procedures had been fully explained.
All subjects were asked to sign the consent form, confirm-
ing that they understood the goals, risks, and potential
benefits of the study and their right to withdraw from the
study at any time. The Ethical Committee of Tehran Uni-
versity approved the study.
Consenting participants were randomized to one of two
sequences: placebo followed by melatonin or melatonin
followed by placebo. The randomization list was com-
pleted using a random number generator. The treatment
phase of each sequence consisted of taking a 5 mg tablet
of melatonin about 30 minutes before habitual nighttime
sleep. The placebo phase consisted of taking an identical
looking placebo on the same schedule. Both melatonin
and placebo were taken on the first night after night work.
All participants had 3 visits to the hospital. At the first
visit, eligibility was checked, participants gave informed
consent, and baseline insomnia parameters were assessed
by using seven questions [32]. Participants were asked to
scale their difficulties in falling asleep, staying asleep and
waking up too early with scores from 1 (no problem) to 5
(very severe problem). They were also asked to specify
their sleep quality (satisfaction with their sleep) using
scores from 1 (very satisfied) to 5 (very unsatisfied) and
were asked to answer the following three questions about
their habitual night time sleep: 1) How long does it take
you to fall asleep? 2) How many times do you wake up
during the night? 3) How many hours do you sleep?
All the participants who reported sleep problems in the
baseline questionnaire were included in the study. In the
first visit, one placebo or one melatonin was given to the
nurses. They were asked to use it at home on the first night
after shift work, about 30 minutes before their intended
sleep. On the following morning, upon awakening, each
participant answered the questionnaire. In the second
visit, after the 4 days of washout and receiving their com-
pleted questionnaire, patients entered into another study
period, conducted as in the first. In the third visit, the last
completed questionnaire was received from nurses.
Data Analysis
We used SPSS 11.5 for Windows for statistical analysis.
When the Kolmogorov-Smirnov test confirmed normal-
ity, parametric tests were conducted. One-way analysis of
variance was used to determine the statistical significance
of subjective scores of insomnia from each phase of the
trial. Statistically significant results detected by analysis of
variance (p < 0.05) were further analyzed by using Tukey
post hoc paired comparisons. Results in the text are
expressed as mean +/- standard deviation.
Results
Eigthy-six out of 118 participants completed the study.
Eleven subjects dropped out during the first treatment
phase because they could not attend the scheduled tablet
taking, whereas one did not complete the second treat-
ment phase because of an acute illness unrelated to the
study protocol. Twenty participants did not report sleep-
ing problems in the baseline questionnaire. Table 1
presents a description of the 86 subjects who completedJournal of Circadian Rhythms 2008, 6:10 http://www.jcircadianrhythms.com/content/6/1/10
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the study. Females accounted for 80.2% of the partici-
pants, and the mean age was 30.05 years (range: 24–46
years). Subjective parameters of sleep obtained from the
baseline questionnaire are shown in Table 1.
Differences in sleep data at baseline, while taking placebo,
and while taking melatonin are shown in Tables 2 and 3.
Subjective sleep onset latency (SOL) was 37.5 +/- 41.3
minutes at the baseline. There was evidence of an effect of
melatonin treatment on SOL. Specifically, the mean SOL
for subjects being treated with melatonin was significantly
lower than the mean SOL for subjects given placebo. Fur-
thermore, means for both the subjects given melatonin
and those given placebo were significantly different from
the baseline mean (see Table 2). Although melatonin
treatment did not significantly alter other insomnia varia-
ble compared with baseline values, there was a significant
improvement in sleep quality with melatonin treatment
(see Table 3).
Discussion
In 86 shift-work nurses with insomnia disorders, admin-
istration of 5 mg of melatonin about 30 minutes before a
night time sleep significantly decreased sleep onset
latency (SOL) and increased sleep quality as compared
with placebo. We observed a significant improvement in
falling asleep induced by 5 mg of melatonin (16 min) as
compared to baseline, which supports the well known
capacity of this hormone to change biological rhythms
[33-36].
Placebo was not equal to baseline for SOL. A general
meta-analysis of placebo effects pointed to a nonsignifi-
cant beneficial effect on sleep latency (a 10-min decrease
in subjective estimates of sleep latency) in five clinical tri-
als [37]. Melatonin did not alter the other sleep parame-
ters that we measured. These findings are in accordance
with those of earlier open trials using smaller numbers of
subjects [38,39].
The focus of our analysis was a comparison of assessment
of insomnia parameters (sleep onset, sleep maintenance,
sleep quality) in nurses with shift working at baseline,
after a one-night melatonin treatment, and after a one-
night placebo treatment. Our study revealed no major
impact of melatonin on difficulty staying asleep or waking
up too early. Our results agree with a previous investiga-
tion suggesting that patients with primary insomnia have
a pathophysiologic disturbance that is not reversed by
melatonin [40]. No adverse effects of melatonin were
noted during the treatment.
The fact that we observed a reduction in SOL but no
change in sleep duration after melatonin administration
has at least two possible explanations: either 1) melatonin
caused a small (16 min) phase advance of the circadian
system or 2) random variation obscured a correspond-
ingly small lengthening of total sleep time. Our data do
not provide the basis for favoring either one or the other
of these alternatives.
A limitation of this study is that we were unable to per-
form polysomnography or actigraphy to evaluate sleep
parameters objectively. Our results based on subjective
self-reports were, however, very encouraging. Regarding
Table 1: Demographic and subjective sleep data of subjects (N = 
86)
Mean (SD) or percentage (n)
Sex 80.2% female (69)
Age 30.05 (5.2)
Mean BMI in kg/m2 26.7 (3.1)
Subjective sleep onset latency in min 37.5 (41.3)
Subjective number of awakenings 5.2 (2.1)
Subjective duration of sleep in min 450.5 (82.3)
Table 2: Subjective sleep parameters during a randomized, double-blind, placebo-controlled crossover study of shift work nurses: 
results at baseline and after 1 night melatonin or placebo treatment (N = 86)
Mean SD P(vs.baselinea) P(vs.placeboa)F b Pb
Sleep onset latency Melatonin 21.5 17.7 < 0.05 < 0.05 6.3 0.01
Placebo 49.7 30.3 < 0.05
Baseline 37.5 41.3
Total sleep time Melatonin 392.1 52.4 > 0.05 > 0.05 0.49 NS
Placebo 372 49.4 > 0.05
Baseline 450.5 82.3
Number of awakenings Melatonin 5.1 1.9 > 0.05 > 0.05 0.64 NS
Placebo 5.1 1.9 > 0.05
Baseline 5.2 2.1
a p values for Tukey post hoc analysis.
b Overall test for differencesJournal of Circadian Rhythms 2008, 6:10 http://www.jcircadianrhythms.com/content/6/1/10
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the high prevalence of insomnia in shift workers, more
studies about melatonin effect on different kinds of
insomnia parameters (difficulty falling asleep, difficulty
staying asleep, problem waking up too early, and sleep
quality) causing by shift working is recommended.
Conclusion
Melatonin may be an effective treatment for shift workers
with difficulty falling asleep.
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